Santa Clara, CA-August 27, 2009
NewCardio, Inc., a cardiac diagnostic and services company, announced that a top-three contract research organization has signed a Master Services Agreement (MSA) to use the company's QTinno software suite as its technology in fully automated Thorough QT (TQT) and Phase 1 studies delivered by its centralized ECG core lab.
NewCardio expects to collaborate on the first fully automated study, tentatively scheduled to begin during the third quarter of 2009.
NewCardio’s innovative 3D ECG platform technology is intended to improve the accuracy and increase the diagnostic value of the standard 12-lead electrocardiogram (ECG). QTinno is a software suite that provides an automated analysis of QT intervals and other ECG-based cardiac safety for the pharmaceutical industry and drug regulators.